Steatohepatitis

{{Main|Alcoholic liver disease}}

Chronic alcohol intake commonly causes steatohepatitis.

{{Main|Non-alcoholic fatty liver disease}}

Previously known as non-alcoholic steatohepatitis (NASH), metabolic dysfunction-associated steatohepatitis (MASH) is characterized by liver cell damage or inflammation histologically (on biopsy), but fatty infiltration is usually also present as opposed to MASLD, which is characterized only by fatty infiltration of the liver. Both MASH and MASLD are caused by metabolic disorders such as diabetes, obesity, hypertriglyceridemia, dyslipidemia, or metabolic syndrome, with alcohol not being involved (although alcohol may exacerbate both diseases).{{cite journal |last1=Sheka |first1=Adam C. |last2=Adeyi |first2=Oyedele |last3=Thompson |first3=Julie |last4=Hameed |first4=Bilal |last5=Crawford |first5=Peter A. |last6=Ikramuddin |first6=Sayeed |title=Nonalcoholic Steatohepatitis: A Review |journal=JAMA |date=24 March 2020 |volume=323 |issue=12 |pages=1175 |doi=10.1001/jama.2020.2298}} Both may progress to cirrhosis of the liver, but the risk is much greater with MASH as opposed to MASLD. At 15 years, 11% of people with MASH develop cirrhosis as opposed to less than 1% with MASLD. All-cause mortality in MASH is 25.5 per 1000 person years with a liver-specific mortality of 11.7 per 1000 person years. The most common cause of death in those with MASH is cardiovascular disease. MASH is associated with a 1.7 times overall mortality, 15 times liver-specific mortality, and 12 times risk of liver cancer as compared to MASLD. Those with MASH and MASLD usually do not have symptoms, but people with MASH may sometimes have nonspecific abdominal discomfort or fatigue.

Treatment for MASH and MASLD is primarily with healthy diet, exercise, and weight loss, which have been shown to cause regression of liver cell damage in MASH. General recommendations include improving metabolic risk factors and reducing alcohol intake.{{cite journal | vauthors = Adams LA, Angulo P | title = Treatment of non-alcoholic fatty liver disease | journal = Postgraduate Medical Journal | volume = 82 | issue = 967 | pages = 315–322 | date = May 2006 | pmid = 16679470 | pmc = 2563793 | doi = 10.1136/pgmj.2005.042200 }}{{cite journal | vauthors = Veena J, Muragundla A, Sidgiddi S, Subramaniam S | title = Non-alcoholic fatty liver disease: need for a balanced nutritional source | journal = The British Journal of Nutrition | volume = 112 | issue = 11 | pages = 1858–1872 | date = December 2014 | pmid = 25274101 | doi = 10.1017/S0007114514002591 | doi-access = free }} A weight loss of 5-10% has been found to lead to regression of liver cell damage on biopsy in MASH, with a weight loss greater than 10% being associated with 90% of people having resolution of disease. Bariatric surgery is sometimes used. As of March 2024, there is one medication, resmetirom (Rezdiffra™) commercially available in the US for management of NASH.{{Cite web |last=Commissioner |first=Office of the |date=2024-08-09 |title=FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease |url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease |access-date=2024-09-13 |website=FDA |language=en}} NASH was first described in 1980 in a series of patients of the Mayo Clinic.{{cite journal | vauthors = Ludwig J, Viggiano TR, McGill DB, Oh BJ | title = Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease | journal = Mayo Clinic Proceedings | volume = 55 | issue = 7 | pages = 434–438 | date = July 1980 | pmid = 7382552 }} Its relevance and high prevalence were recognized mainly in the 1990s. Some think NASH is a diagnosis of exclusion, and many cases may, in fact, be due to other causes.{{cite journal | vauthors = Cassiman D, Jaeken J | title = NASH may be trash | journal = Gut | volume = 57 | issue = 2 | pages = 141–144 | date = February 2008 | pmid = 18192446 | doi = 10.1136/gut.2007.123240 | s2cid = 206946004 }}

MASH is expected to be the leading indication for liver transplantation in the United States, surpassing ALD.

• Chronic liver disease

• Aramchol
• Elafibranor

{{reflist|colwidth=30em}}

{{Medical resources

| DiseasesDB = 29786

| ICD10 = {{ICD10|K|70|1|k|70}}, {{ICD10|K|76|0|k|70}}

| ICD9 = {{ICD9|571.0}}, {{ICD9|571.8}}

| ICDO =

| OMIM =

| MedlinePlus =

| eMedicineSubj = article

| eMedicineTopic = 170539

| SNOMED CT = 442191002

}}

{{Digestive system diseases}}

Category:Hepatitis

Category:Diseases of liver

pt:Esteato-hepatite não alcoólica